Drug
Panobinostat clinical trials
Also written LBH589, Farydak and LBH589B.
- studies test it
- 136
- open now
- 3
- in phase 3
- 3
- first study started
- 2003
Keep track of what changes. Save the Panobinostat studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
135 studies that test it; most in 2009 (27)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2006 | 3 |
| 2007 | 12 |
| 2008 | 20 |
| 2009 | 27 |
| 2010 | 20 |
| 2011 | 13 |
| 2012 | 7 |
| 2013 | 5 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 10 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 81
- Phase 2
- 76
- Phase 3
- 3
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 42 · Other 94
Novartis Pharmaceuticals (39) · M.D. Anderson Cancer Center (7) · H. Lee Moffitt Cancer Center and Research Institute (7) · SCRI Development Innovations, LLC (6) · Dana-Farber Cancer Institute (4) · City of Hope Medical Center (3) · Massachusetts General Hospital (2) · Mayo Clinic (2)
Often tested with
Tested in the same studies.
Bortezomib (12) · Everolimus (11) · Dexamethasone (10) · Lenalidomide (7) · Carfilzomib (5) · Ruxolitinib (4) · Gemcitabine (4) · Bevacizumab (4)
Studies
Open first, then newest update. How each study uses Panobinostat is read from its arms, and is right about nine times in ten.
Testing it · 136
- Study of Panobinostat (LBH589) in Patients With Sickle Cell DiseaseRecruitingPhase 1Abdullah KutlarNCT01245179Written as panobinostat
- Optimizing Reversal of HIV Latency With Combination TherapyNot yet recruitingPhase 1/2Erasmus Medical CenterNCT06240520Written as Panobinostat 20 MG Oral Capsule
- Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal CancerRecruitingPhase 2Oslo University HospitalNCT05725200Written as Panobinostat
- CINC424A2X01B Rollover ProtocolActive, not recruitingPhase 4Novartis PharmaceuticalsNCT02386800Written as panobinostat
- Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG)TerminatedPhase 1Columbia UniversityNCT04804709Written as Panobinostat 15 MG
- Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple MyelomaCompletedPhase 2M.D. Anderson Cancer CenterNCT02506959Written as Panobinostat
- A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRTTerminatedPhase 2Australian & New Zealand Children's Haematology/Oncology GroupNCT04897880Written as Panobinostat
- Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple MyelomaCompletedPhase 2pharmaand GmbHNCT02654990Written as Panobinostat Capsules
- Trial of Panobinostat in Children With Diffuse Intrinsic Pontine GliomaCompletedPhase 1Pediatric Brain Tumor ConsortiumNCT02717455Written as LBH589
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedPhase 1OHSU Knight Cancer InstituteNCT03878524Written as Panobinostat
- Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral TherapyCompletedPhase 1/2Massachusetts General HospitalNCT02471430Written as Panobinostat
- Phase I Study of Marizomib + Panobinostat for Children With DIPGTerminatedPhase 1Dana-Farber Cancer InstituteNCT04341311Written as Panobinostat
- Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)CompletedPhase 1/2John MascarenhasNCT01693601Written as Panobinostat
- Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple MyelomaCompletedPhase 1M.D. Anderson Cancer CenterNCT01301807Written as Panobinostat
- Panobinostat Maintenance After HSCT fo High-risk AML and MDSTerminatedPhase 3Goethe UniversityNCT04326764Written as Panobinostat
- Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV MelanomaCompletedPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT02032810Written as Panobinostat
- A Study of PDR001 in Combination With LCL161, Everolimus or PanobinostatCompletedPhase 1Novartis PharmaceuticalsNCT02890069Written as Panobinostat
- Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)CompletedPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT02722941Written as Panobinostat
- Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib TosylateTerminatedPhase 1/2Roswell Park Cancer InstituteNCT01582009Written as panobinostat
- Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedPhase 2Mayo ClinicNCT01261247Written as panobinostat
See all 136 studies that test Panobinostat →
Given in every arm · 6 — Panobinostat is usual care beside what is tested
- Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain TumorsTerminatedPhase 1Sidney Kimmel Cancer Center at Thomas Jefferson UniversityNCT01324635Written as Panobinostat
- Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple MyelomaTerminatedPhase 1Abdullah KhanNCT04956302Written as Panobinostat Lactate
- A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL)CompletedPhase 2Sarit AssoulineNCT01238692Written as LBH589
- LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS)TerminatedPhase 2Novartis PharmaceuticalsNCT01034657Written as LBH589
- A Study Of Panobinostat In Children With Refractory Hematologic MalignanciesCompletedPhase 1Therapeutic Advances in Childhood Leukemia ConsortiumNCT01321346Written as Panobinostat
- LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer PatientsCompletedPhase 1SCRI Development Innovations, LLCNCT00632489Written as LBH589
Codes
What other systems call Panobinostat · ClinicalTrials.gg INT006802
- MeSH (NLM) D000077767PanobinostatConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 9647FM7Y3ZPANOBINOSTATConfirmed FDA, NLM, Wikidata
- RxNorm 1603350Confirmed FDA, Wikidata
- Wikidata Q7131441panobinostatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C66948PanobinostatOne source FDA
- DrugBank DB06603One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077767 | Panobinostat | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 9647FM7Y3Z | PANOBINOSTAT | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1603350 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7131441 | panobinostat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C66948 | Panobinostat | One source FDA |
| DrugBank | DB06603 | — | One source Wikidata |
Also registered as panobinostat hydrate (UNII D07V79Q44T) and panobinostat lactate (UNII HN0T99OO4V · RxNorm 1603349).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.